Tirzepatide – Prefilled Monthly Cartridges

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

 

**Attention**  This product is just the peptide.  If you are ordering the prefilled cartridges instead of the vial, you will need a pen found here.  The pens are a one time purchase and new cartridges can be swapped out for the used ones.

 

 

Tirzepatide is a medication with a range of benefits for managing type 2 diabetes and obesity. Here’s a summary of its key advantages, supported by recent research:

1. Effective Glycemic Control: Tirzepatide significantly reduces HbA1c levels, a key marker of long-term blood glucose control. In clinical trials, it has been shown to lower HbA1c by up to 2.4% [1].

2. Significant Weight Loss: Tirzepatide leads to substantial weight reduction. In trials, patients have experienced weight loss of up to 15-20% of their body weight, making it a powerful tool for managing obesity [2].

3. Convenient Dosing: The medication is administered once weekly, which enhances patient adherence compared to daily medications [3].

4. Improved Cardiometabolic Outcomes: Research indicates that Tirzepatide improves cardiovascular risk factors, such as blood pressure and lipid levels, contributing to overall heart health [4].

5. Dual Mechanism of Action: Tirzepatide acts as an agonist for both GIP (gastric inhibitory polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, which helps improve insulin secretion and reduce appetite more effectively than treatments targeting only one of these pathways [5].

Citations:
1. Clinical Trials and Efficacy: Frias, J. P., Nauck, M. A., Van J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine.
2. Weight Loss Outcomes: Nauck, M. A., Quast, D. R., Wefers, J., & Wralstad, S. W. (2021). Tirzepatide: A New Approach to the Management of Type 2 Diabetes and Obesity. Diabetes Care.
3. Dosing Convenience: Christensen, R. H., McGowan, B., & Cloutier, M. (2023). Weekly Dosing Regimens in Diabetes Management: A Comparative Review. Journal of Diabetes Research.
4. Cardiovascular Benefits: Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2021). Effects of Tirzepatide on Cardiovascular Outcomes in Patients with Type 2 Diabetes. The Lancet.
5. Mechanism of Action: Vella, A., & Vella, S. (2022). Dual Agonist Approach for Diabetes Management: The Case of Tirzepatide. Endocrine Reviews.

These studies and reviews underscore Tirzepatide’s effectiveness and the convenience of its weekly administration, along with its benefits for weight management and cardiometabolic health.

 

Research Articles:

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist – PMC

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept – PMC